MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Roniciclib

CAS No. : 1223498-69-8

MCE 站：Roniciclib

产品活性：Roniciclib 是具有口服活性的，细胞周期蛋白 (CDK) 的广泛性抑制剂，其对 CDK1，CDK2，CDK3，CDK4，CDK7 和 CDK9 的 IC₅₀ 值为 5-25 nM。

研究领域：Cell Cycle/DNA Damage

作用靶点：CDK

In Vitro: Roniciclib (BAY 1000394) inhibits the kinase activity of the cell-cycle CDKs CDK1/cyclin B, CDK2/cyclin E, ａnd CDK4/cyclinDwith IC₅₀ values of 7, 9, ａnd 11 nM, respectively. The transcriptional CDKs CDK9/cyclin T1 ａnd CDK7/cyclin H/MAT1 are inhibited in a similar range (5 ａnd 25 nM).
Roniciclib potently inhibits the proliferation of various human ａnd murine tumor cell lines with a very balanced profile (mean IC₅₀ on human tumor cells: 16 nM).

In Vivo: Tumor growth is strongly inhibited in a dose-dependent manner with T/C values of 0.19 at the lower dose ａnd of 0.02 (tumor regression) at the higher dose. Furthermore, Roniciclib strongly inhibits growth of HeLa-MaTu tumors that have been grown to a size of approximately 50mm² before start of treatment (day 8 after inoculation). Treatment with Roniciclib at doses of 1.5 ａnd 1 mg/kg slow tumor growth to T/C values of 0.15 ａnd 0.62, respectively. Addition of Roniciclib to cisplatin result in a strong tumor growth inhibition with T/C values of 0.01 (1.0 mg/kg Roniciclib) ａnd -0.02 (1.5 mg/kg Roniciclib).
Roniciclib has low blood clearance rates in mouse, rat, ａnd dog (0.51, 0.78, ａnd 0.50 Lh^-1kg^-1, respectively) .

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Kinase Inhibitor Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Membrane Protein-targeted Compound Library  |  Serine/Threonine Kinase Inhibitor Library  |  SY-5609  |  CLK1/2-IN-1  |  MFH290  |  SB-218078  |  Toyocamycin  |  (S)-LY3177833 hydrate  |  Dinaciclib  |  EGFR/HER2/CDK9-IN-2  |  CDK8-IN-11  |  SNS-032  |  M2N12  |  Palbociclib-d₈  |  EGFR/CDK2-IN-1  |  BSJ-04-132  |  (E/Z)-Zotiraciclib  |  CCT-251921  |  BS-181  |  A09-003  |  (R)-PROTAC CDK9 ligand-1  |  Ribociclib-d₈  |  CDK9-IN-9  |  Flavopiridol  |  SRI-29329  |  dCeMM4  |  GSK 3 Inhibitor IX  |  CDK9-IN-7  |  PROTAC CDK9 degrader-8  |  BSJ-03-204  |  Amantadine-d₆  |  K00546

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。